Core Insights - Hologic (HOLX) is currently trading at $75.05, which is 1.2% below the buyout cash offer of $76 per share from Blackstone & TPG, announced in October 2025, with a potential aggregate purchase price of up to $79 per share, representing a 46% premium to the closing price on May 23, 2025 [1][11] Company Overview - Hologic, based in Marlborough, MA, specializes in diagnostic products for women's health, including molecular diagnostics tests and medical imaging systems [2] - Blackstone has monitored Hologic for years, while TPG sees it as a compelling opportunity for healthcare innovation [2] Shareholder Approval - Hologic shareholders approved the take-private proposal at a special stockholder meeting on February 5, 2026, marking a significant step toward closing the deal [3] Price Performance & Valuation - Hologic shares have increased by 0.7% year-to-date, outperforming industry peers GE HealthCare and Becton, Dickinson & Company, which have seen declines of 11.8% and 16.7%, respectively [4] - The stock trades at a forward 12-month price/sales (P/S) ratio of 3.84X, above its median of 3.54X and the sector average of 2.28X, indicating a stretched valuation [8] Financial Performance - Hologic's Diagnostics revenues fell by 2.7%, with the core Molecular Diagnostics business declining by 4.6% due to lower sales of COVID-19 tests and legacy assays [13] - Tariff costs amounted to $15.3 million in the first quarter of fiscal 2026, with expectations of ongoing costs between $10-$14 million per quarter [17] - The company ended the quarter with cash and short-term investments of $2.36 billion and $6 million in current debt [17] Innovations and Product Development - Hologic is set to launch the Envision Mammography Platform, featuring a 2.5-second scan time, and has received FDA approval for the Aptima HPV Assay for primary screening [14][16] - The acquisition of Endomagnetics has enhanced Hologic's Interventional Breast business, contributing to its diversification strategy [15] Earnings Projections - The Zacks Consensus Estimate projects a 5.2% increase in fiscal 2026 earnings, with a revenue growth of 4% and an expected earnings per share (EPS) of $4.48 [18]

Apple is preparing to absorb $1.1 billion in tariff costs this quarter, CEO Tim Cook told investors on Thursday's earnings call. https://t.co/RqzazWXC5b ...

Financial Performance - Hershey lowered its full year profit guidance due to higher tariff costs than previously estimated [1]